BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.

Rolf Ljung; G Kenet; M E Mancuso; V Kaleva; L Rusen; D Tseneklidou-Stoeter; L A Michaels; A Shah; W Hong; M Maas Enriquez

doi:10.1111/hae.12866

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.

Rolf Ljung, G Kenet, M E Mancuso, V Kaleva, L Rusen, D Tseneklidou-Stoeter, L A Michaels, A Shah, W Hong, M Maas Enriquez

Research output: Contribution to journal › Article › peer-review

Abstract

BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.

Original language	English
Pages (from-to)	354-360
Journal	Haemophilia
Volume	22
Issue number	3
Early online date	2015 Dec 9
DOIs	https://doi.org/10.1111/hae.12866
Publication status	Published - 2016

Subject classification (UKÄ)

Hematology

Access to Document

10.1111/hae.12866

http://www.ncbi.nlm.nih.gov/pubmed/26663410?dopt=Abstract

Cite this

Ljung, R., Kenet, G., Mancuso, M. E., Kaleva, V., Rusen, L., Tseneklidou-Stoeter, D., Michaels, L. A., Shah, A., Hong, W., & Maas Enriquez, M. (2016). BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia, 22(3), 354-360. https://doi.org/10.1111/hae.12866

@article{8a447c6b758b4a77aa6ed853b29f00b7,

title = "BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.",

abstract = "BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.",

author = "Rolf Ljung and G Kenet and Mancuso, {M E} and V Kaleva and L Rusen and D Tseneklidou-Stoeter and Michaels, {L A} and A Shah and W Hong and {Maas Enriquez}, M",

year = "2016",

doi = "10.1111/hae.12866",

language = "English",

volume = "22",

pages = "354--360",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley & Sons Inc.",

number = "3",

}

Ljung, R, Kenet, G, Mancuso, ME, Kaleva, V, Rusen, L, Tseneklidou-Stoeter, D, Michaels, LA, Shah, A, Hong, W & Maas Enriquez, M 2016, 'BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.', Haemophilia, vol. 22, no. 3, pp. 354-360. https://doi.org/10.1111/hae.12866

TY - JOUR

T1 - BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.

AU - Ljung, Rolf

AU - Kenet, G

AU - Mancuso, M E

AU - Kaleva, V

AU - Rusen, L

AU - Tseneklidou-Stoeter, D

AU - Michaels, L A

AU - Shah, A

AU - Hong, W

AU - Maas Enriquez, M

PY - 2016

Y1 - 2016

N2 - BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.

AB - BAY 81-8973, a full-length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino acid sequence as Bayer's sucrose-formulated recombinant FVIII but is produced with more advanced manufacturing technologies.

U2 - 10.1111/hae.12866

DO - 10.1111/hae.12866

M3 - Article

C2 - 26663410

SN - 1351-8216

VL - 22

SP - 354

EP - 360

JO - Haemophilia

JF - Haemophilia

IS - 3

ER -

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this